- Home
- EVOK vs CDT Comparison
EVOK vs CDT Comparison
Compare EVOK & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- CDT
- Stock Information
- Founded
- EVOK 2007
- CDT 2019
- Country
- EVOK United States
- CDT United States
- Employees
- EVOK N/A
- CDT N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- CDT Health Care
- Exchange
- EVOK Nasdaq
- CDT Nasdaq
- Market Cap
- EVOK 5.4M
- CDT 4.6M
- IPO Year
- EVOK 2013
- CDT N/A
- Fundamental
- Price
- EVOK $5.12
- CDT $0.70
- Analyst Decision
- EVOK
- CDT
- Analyst Count
- EVOK 0
- CDT 0
- Target Price
- EVOK N/A
- CDT N/A
- AVG Volume (30 Days)
- EVOK 432.5K
- CDT 12.0M
- Earning Date
- EVOK 11-06-2025
- CDT 11-13-2025
- Dividend Yield
- EVOK N/A
- CDT N/A
- EPS Growth
- EVOK N/A
- CDT N/A
- EPS
- EVOK N/A
- CDT N/A
- Revenue
- EVOK $12,794,859.00
- CDT N/A
- Revenue This Year
- EVOK $57.38
- CDT N/A
- Revenue Next Year
- EVOK $59.57
- CDT N/A
- P/E Ratio
- EVOK N/A
- CDT N/A
- Revenue Growth
- EVOK 70.02
- CDT N/A
- 52 Week Low
- EVOK $1.94
- CDT $0.57
- 52 Week High
- EVOK $12.32
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- EVOK 49.82
- CDT 30.88
- Support Level
- EVOK $5.00
- CDT $0.57
- Resistance Level
- EVOK $5.27
- CDT $1.18
- Average True Range (ATR)
- EVOK 0.22
- CDT 0.11
- MACD
- EVOK -0.05
- CDT 0.00
- Stochastic Oscillator
- EVOK 38.91
- CDT 15.27
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.